StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $6.16 | $5.96 | -3.25% | 3.3M |
| 05-18 | $5.91 | $5.45 | -7.87% | 2.3M |
| 05-19 | $5.41 | $5.18 | -4.16% | 2.3M |
| 05-20 | $5.25 | $5.49 | +4.57% | 3.1M |
| 05-21 | $5.37 | $5.59 | +4.19% | 1.0M |
No sell-side coverage available for TSHA yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $9.77M | $4.29M | $4.29M |
Operating Income | $-43.49M | $-110.50M | $-82.20M | $-48.17M |
Net Income | $-42.41M | $-109.00M | $-81.14M | $-48.41M |
EPS (Diluted) | $-0.12 | $-0.34 | $-0.26 | $-0.17 |
Total Assets | $300.35M | $343.32M | $316.55M | $333.33M |
Total Liabilities | $88.41M | $96.38M | $97.56M | $84.60M |
Cash & Equivalents | $276.58M | $319.77M | $297.34M | $312.76M |
Free Cash Flow OCF − CapEx | $-40.90M | $-93.83M | $-66.86M | $-42.58M |
Shares Outstanding | 287.28M | 285.05M | 273.92M | 272.73M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.